Helius Medical Technologies, formerly focused on biotech, has announced a pivot toward digital asset management centered on Solana, supported by a $500 million PIPE funding.
Helius's Strategic Shift
Helius Medical Technologies has made a bold shift from a biotech focus to digital asset treasury operations, confirming its strategy centered on Solana in September 2025.
Investments and Leadership Changes
The company raised over $500 million through PIPE, led by Pantera Capital and Summer Capital, with notable participation from Animoca Brands and FalconX. Joseph Chee has been appointed as Executive Chairman.
Impact on Solana and Digital Asset Markets
Helius's pivot towards Solana opens new avenues for staking and DeFi, with an expected yield of about 7%. This strategic move may significantly enhance Solana's position as a reserve asset and influence treasury strategies among public firms.
This strategic shift in treasury management promises growth for Solana and potential changes in corporate approaches to digital assets.
